Tajima Tomoo, Suzuki Yasuhiro, Tokuda Yutaka
Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan.
Gan To Kagaku Ryoho. 2002 Jul;29(7):1132-7.
Herceptin (trastuzumab) is a recombinant humanized murine monoclonal antibody that recognizes HER2/neu cell-surface receptors and has been shown to be active both in combination with adriamycin (epirubicin)/cyclophosphamide or taxanes and as a single agent, either in the 1st or 2nd/3rd line treatment of women with metastatic breast cancer with HER2 overexpression by IHC or gene amplification by FISH. Preliminary results of Herceptin with other agents such as vinorelbine, cisplatin and various hormonal agents are also promising, and these combinations warrant further clinical exploration. Large-scale multicenter trials including a European and an international study in adjuvant setting have started for high-risk women with HER2 overexpressing breast cancer, with total planned recruitment of nearly 10,000 women.
赫赛汀（曲妥珠单抗）是一种重组人源化鼠单克隆抗体，可识别HER2/neu细胞表面受体，已证明其与阿霉素（表柔比星）/环磷酰胺或紫杉烷联合使用时具有活性，并且作为单一药物，可用于通过免疫组化（IHC）检测HER2过表达或通过荧光原位杂交（FISH）检测基因扩增的转移性乳腺癌女性患者的一线或二线/三线治疗。赫赛汀与其他药物（如长春瑞滨、顺铂和各种激素药物）联合使用的初步结果也很有前景，这些联合用药值得进一步的临床探索。针对HER2过表达的高危乳腺癌女性患者，已启动了包括一项欧洲研究和一项国际辅助治疗研究在内的大规模多中心试验，计划总共招募近10000名女性患者。
